The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation.
Baier D, Schoenhacker-Alte B, Rusz M, Pirker C, Mohr T, Mendrina T, Kirchhofer D, Meier-Menches SM, Hohenwallner K, Schaier M, Rampler E, Koellensperger G, Heffeter P, Keppler B, Berger W.
Baier D, et al. Among authors: rampler e.
Pharmaceutics. 2022 Jan 20;14(2):238. doi: 10.3390/pharmaceutics14020238.
Pharmaceutics. 2022.
PMID: 35213972
Free PMC article.